Cargando…

初治多发性骨髓瘤患者早期死亡预测模型的建立

OBJECTIVE: To investigate risk factors for early mortality (EM) in patients with newly diagnosed multiple myeloma (NDMM) and to build an EM-predictive model. METHODS: In a cohort of 275 patients with NDMM, risk factors for EM at 6, 12, and 24 months after diagnosis (EM6, EM12, and EM24, respectively...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501273/
https://www.ncbi.nlm.nih.gov/pubmed/34547873
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2021.08.009
_version_ 1784580642513616896
collection PubMed
description OBJECTIVE: To investigate risk factors for early mortality (EM) in patients with newly diagnosed multiple myeloma (NDMM) and to build an EM-predictive model. METHODS: In a cohort of 275 patients with NDMM, risk factors for EM at 6, 12, and 24 months after diagnosis (EM6, EM12, and EM24, respectively) were determined to establish a model to predict EM. RESULTS: The rates of EM6, EM12, and EM24 were 5.5%, 12.7%, and 30.2%, respectively. The most common cause for EM was disease progression/relapse, accounting for 60.0%, 77.1%, and 84.3% of EM6, EM12, and EM24, respectively. EM6 was associated with corrected serum calcium >2.75 mmol/L and platelet count <100×10(9)/L, whereas risk factors for EM12 included age >75 years, ISS Ⅲ, R-ISS Ⅲ, corrected serum calcium >2.75 mmol/L, serum creatinine >177 µmol/L, platelet count <100×10(9)/L, and bone marrow plasma cell ratio ≥ 60%. In addition to the risk factors for EM12, EM24 was also associated with male sex and 1q21 gain. By multivariate analysis, age >75 years, platelet count <100×10(9)/L, and 1q21 gain were independent risk factors for EM24 but there were no independent risk factors significantly associated with EM6 and EM12. Using a scoring system including these three risk factors, a Cox model for EM24 was generated to distinguish patients with low (score<3) and high (score ≥ 3) risk. The sensitivity and specificity of the model were 20.7% and 99.2%, respectively. Further, an internal validation performed in a cohort of 183 patients with NDMM revealed that the probability of EM24 in high-risk patients was 26 times higher than that in low-risk patients. Moreover, this model was also able to predict overall survival. The median overall survival of patients with scores of 0, 1, 2, 3, 4, and 5 were 59, 41, 22, 17.5, and 16 months, respectively. CONCLUSION: In the study cohort, the EM6, EM12, and EM24 rates were 5.5%, 12.7%, and 30.2%, respectively, and disease progression or relapse were main causes of EM. An EM24-predictive model built on three independent risk factors for EM24 (age>75 years, platelet count<100×10(9)/L, and 1q21 gain) might predict EM risk and overall survival.
format Online
Article
Text
id pubmed-8501273
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-85012732021-10-15 初治多发性骨髓瘤患者早期死亡预测模型的建立 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To investigate risk factors for early mortality (EM) in patients with newly diagnosed multiple myeloma (NDMM) and to build an EM-predictive model. METHODS: In a cohort of 275 patients with NDMM, risk factors for EM at 6, 12, and 24 months after diagnosis (EM6, EM12, and EM24, respectively) were determined to establish a model to predict EM. RESULTS: The rates of EM6, EM12, and EM24 were 5.5%, 12.7%, and 30.2%, respectively. The most common cause for EM was disease progression/relapse, accounting for 60.0%, 77.1%, and 84.3% of EM6, EM12, and EM24, respectively. EM6 was associated with corrected serum calcium >2.75 mmol/L and platelet count <100×10(9)/L, whereas risk factors for EM12 included age >75 years, ISS Ⅲ, R-ISS Ⅲ, corrected serum calcium >2.75 mmol/L, serum creatinine >177 µmol/L, platelet count <100×10(9)/L, and bone marrow plasma cell ratio ≥ 60%. In addition to the risk factors for EM12, EM24 was also associated with male sex and 1q21 gain. By multivariate analysis, age >75 years, platelet count <100×10(9)/L, and 1q21 gain were independent risk factors for EM24 but there were no independent risk factors significantly associated with EM6 and EM12. Using a scoring system including these three risk factors, a Cox model for EM24 was generated to distinguish patients with low (score<3) and high (score ≥ 3) risk. The sensitivity and specificity of the model were 20.7% and 99.2%, respectively. Further, an internal validation performed in a cohort of 183 patients with NDMM revealed that the probability of EM24 in high-risk patients was 26 times higher than that in low-risk patients. Moreover, this model was also able to predict overall survival. The median overall survival of patients with scores of 0, 1, 2, 3, 4, and 5 were 59, 41, 22, 17.5, and 16 months, respectively. CONCLUSION: In the study cohort, the EM6, EM12, and EM24 rates were 5.5%, 12.7%, and 30.2%, respectively, and disease progression or relapse were main causes of EM. An EM24-predictive model built on three independent risk factors for EM24 (age>75 years, platelet count<100×10(9)/L, and 1q21 gain) might predict EM risk and overall survival. Editorial office of Chinese Journal of Hematology 2021-08 /pmc/articles/PMC8501273/ /pubmed/34547873 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2021.08.009 Text en 2021年版权归中华医学会所有 https://creativecommons.org/licenses/by/3.0/This work is licensed under a Creative Commons Attribution 3.0 License.
spellingShingle 论著
初治多发性骨髓瘤患者早期死亡预测模型的建立
title 初治多发性骨髓瘤患者早期死亡预测模型的建立
title_full 初治多发性骨髓瘤患者早期死亡预测模型的建立
title_fullStr 初治多发性骨髓瘤患者早期死亡预测模型的建立
title_full_unstemmed 初治多发性骨髓瘤患者早期死亡预测模型的建立
title_short 初治多发性骨髓瘤患者早期死亡预测模型的建立
title_sort 初治多发性骨髓瘤患者早期死亡预测模型的建立
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501273/
https://www.ncbi.nlm.nih.gov/pubmed/34547873
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2021.08.009
work_keys_str_mv AT chūzhìduōfāxìnggǔsuǐliúhuànzhězǎoqīsǐwángyùcèmóxíngdejiànlì
AT chūzhìduōfāxìnggǔsuǐliúhuànzhězǎoqīsǐwángyùcèmóxíngdejiànlì
AT chūzhìduōfāxìnggǔsuǐliúhuànzhězǎoqīsǐwángyùcèmóxíngdejiànlì
AT chūzhìduōfāxìnggǔsuǐliúhuànzhězǎoqīsǐwángyùcèmóxíngdejiànlì
AT chūzhìduōfāxìnggǔsuǐliúhuànzhězǎoqīsǐwángyùcèmóxíngdejiànlì
AT chūzhìduōfāxìnggǔsuǐliúhuànzhězǎoqīsǐwángyùcèmóxíngdejiànlì
AT chūzhìduōfāxìnggǔsuǐliúhuànzhězǎoqīsǐwángyùcèmóxíngdejiànlì
AT chūzhìduōfāxìnggǔsuǐliúhuànzhězǎoqīsǐwángyùcèmóxíngdejiànlì
AT chūzhìduōfāxìnggǔsuǐliúhuànzhězǎoqīsǐwángyùcèmóxíngdejiànlì
AT chūzhìduōfāxìnggǔsuǐliúhuànzhězǎoqīsǐwángyùcèmóxíngdejiànlì
AT chūzhìduōfāxìnggǔsuǐliúhuànzhězǎoqīsǐwángyùcèmóxíngdejiànlì
AT chūzhìduōfāxìnggǔsuǐliúhuànzhězǎoqīsǐwángyùcèmóxíngdejiànlì